Biomedical Engineering Reference
In-Depth Information
67. Kaser A, Nagata S, Tilg H. (1999) Interferon alpha augments
activation-induced T cell death by upregulation of Fas
(CD95/APO-1) and Fas ligand expression. Cytokine 11(10),
736-743.
68. Dondi E, Roue G, Yuste VJ, Susin SA, Pellegrini S. (2004) A
dual role of IFN-alpha in the balance between proliferation
and death of human CD4
รพ
T lymphocytes during primary
response. J. Immunol. 173(6), 3740-3747.
69. Radojkovic C, Genoux A, Pons V, Combes G, de Jonge H,
Champagne E, et al. (2009) Stimulation of cell surface F1-
ATPase activity by apolipoprotein A-I inhibits endothelial
cell apoptosis and promotes proliferation. Arterioscler.
Thromb. Vasc. Biol. 29(7), 1125-1130.
70. Acton SL, Scherer PE, Lodish HF, Krieger M. (1994) Expres-
sion cloning of SR-BI, a CD36-related class B scavenger
receptor. J. Biol. Chem. 269(33), 21003-21009.
71. Schonfeld G, Pfleger B, Roy R. (1975) Structure of human
high density lipoprotein reassembled in vitro. Radio-
immunoassay studies. J. Biol. Chem. 250(19), 7934-7950.
72. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper
CJ, Yasin M, et al. (2003) Effect of recombinant ApoA-I
Milano on coronary atherosclerosis in patients with acute
coronary syndromes: a randomized controlled trial. JAMA
290(17), 2292-2300.
73. Eriksson M, Carlson LA, Miettinen TA, Angelin B. (1999)
Stimulation of fecal steroid excretion after infusion of recom-
binant proapolipoprotein A-I. Potential reverse cholesterol
transport in humans. Circulation 100(6), 594-598.
74. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T,
Kapadia S, et al. (2006) Relationship between atheroma
regression and change in lumen size after infusion of
apolipoprotein A-I Milano. J. Am. Coll. Cardiol. 47(5),
992-997.
75. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG,
Binggeli C, et al. (2002) High-density lipoprotein restores
endothelial function in hypercholesterolemic men. Circula-
tion 105(12), 1399-1402.
76. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J,
Heinonen TM, et al. (2007) Effects of reconstituted high-
density lipoprotein infusions on coronary atherosclerosis: a
randomized controlled trial. JAMA 297(15), 1675-1682.
77. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G,
Olszewski WL, et al. (2001) Intravenous apoA-I/lecithin
discs increase pre-beta-HDL concentration in tissue fluid
and stimulate reverse cholesterol
80. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P,
Mukhamedova N, et al. (2008) Infusion of reconstituted high-
density lipoprotein leads to acute changes in human athero-
sclerotic plaque. Circ. Res. 103(10), 1084-1091.
81. Panagotopulos SE, Witting SR, Horace EM, Nicholas Maior-
ano J, Sean Davidson W. (2002) Bacterial expression and
characterization of mature apolipoprotein A-I. Protein Expr.
Purif. 25(2), 353-361.
82. Ryan RO, Forte TM, Oda MN. (2003) Optimized bacterial
expression of human apolipoprotein A-I. Protein Expr. Purif.
27(1), 98-103.
83. Feng MQ, Cai QS, Song DX, Dong JB, Zhou P. (2006) High
yield and secretion of recombinant human apolipoprotein AI
in Pichia pastoris. Protein Expr. Purif. 46(2), 337-342.
84. Pyle LE, Fidge NH, Barton PA, Luong A, Sviridov D. (1997)
Production of mature human apolipoprotein A-I in a bacu-
lovirus-insect cell system: propeptide is not essential for
intracellular processing but may assist
rapid secretion.
Anal. Biochem. 253(2), 253-258.
85. Schmidt HH, Genschel J, Haas R, Buttner C, Manns MP.
(1997) Expression and purification of recombinant human
apolipoprotein A-I in Chinese hamster ovary cells. Protein
Expr. Purif. 10(2), 226-236.
86. Mallory JB, Kushner PJ, Protter AA, Cofer CL, Appleby VL,
Lau K, et al. (1987) Expression and characterization of
human apolipoprotein A-I in Chinese hamster ovary cells.
J. Biol. Chem. 262(9), 4241-4247.
87. Chiaiese P, Minutolo M, Arciello A, Guglielmini F, Piccoli R,
Filippone E. (2011) Expression of human apolipoprotein A-I
in Nicotiana tabacum. Biotechnol. Lett. 33(1), 159-165.
88. Nykiforuk CL, Shen Y, Murray EW, Boothe JG, Busseuil D,
Rheaume E, et al. (2011) Expression and recovery of biolog-
ically active recombinant Apolipoprotein AI(Milano) from
transgenic safflower (Carthamus tinctorius) seeds. Plant
Biotechnol. J. 9(2), 250-263.
89. Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, et
al. (2008) Stable high volumetric production of glycosylated
human recombinant IFNalpha2b in HEK293 cells. BMC
Biotechnol. 8, 65.
90. Salunkhe S, Soorapaneni S, Prasad KS, Raiker VA, Padma-
nabhan S. (2011) Strategies to maximize expression of rightly
processed human interferon alpha2b in Pichia pastoris. Pro-
tein Expr. Purif. 71(2), 139-146.
91. Ohya K, Matsumura T, Ohashi K, Onuma M, Sugimoto C.
(2001) Expression of two subtypes of human IFN-alpha in
transgenic potato plants. J. Interferon Cytokine Res. 21(8),
595-602.
92. Gresser I, Bourali C, Levy JP, Fontaine-Brouty-Boye D,
Thomas MT. (1969) Increased survival in mice inoculated
with tumor cells and treated with interferon preparations.
Proc. Natl. Acad. Sci. U S A 63(1), 51-57.
93. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S,
et al. (2011) Telaprevir for retreatment of HCV infection.
N. Engl. J. Med. 364(25), 2417-2428.
94. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie
AM, Reddy KR, Bzowej NH, et al. (2011) Telaprevir for
transport
in humans.
J. Lipid Res. 42(10), 1586-1593.
78. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen
I, Hayden MR, et al. (2003) Restoration of endothelial
function by increasing high-density lipoprotein in subjects
with isolated low high-density lipoprotein. Circulation
107(23), 2944-2948.
79. Patel S, Drew BG, Nakhla S, Duffy SJ, Murphy AJ, Barter PJ,
et al. (2009) Reconstituted high-density lipoprotein increases
plasma high-density lipoprotein anti-inflammatory properties
and cholesterol efflux capacity in patients with type 2 diabe-
tes. J. Am. Coll. Cardiol. 53(11), 962-971.
Search WWH ::
Custom Search